Efficacy Study of Olutasidenib and Temozolomide in IDH1-Mutant High-Grade Glioma
A study is underway to evaluate the efficacy of olutasidenib combined with temozolomide in treating IDH1-mutant high-grade glioma in pediatric and young adult patients.
Asset / Drug
Drug and asset intelligence for olutasidenib with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.